BioSpace News Archive

Seres Therapeutics, Inc., announced that the Company has completed enrollment of its SER-109 Phase 3 clinical study, ECOSPOR III.

Generation Bio and Vir Biotechnology announced a collaborative research agreement to explore the potential for Generation Bio’s non-viral gene therapy platform to extend the impact and reach of Vir’s current or future human monoclonal antibodies against SARS-CoV-2, the virus responsible for COVID-19.

Proceeds to support completion of next generation cell and gene research and manufacturing platform at ElevateBio BaseCamp and accelerate product development

Phase 2 cohorts evaluating the combination in patients with pancreatic cancer, cholangiocarcinoma, and microsatellite stable colorectal cancer to begin enrollment

Approval makes novel non-invasive vagus nerve stimulation therapy available for prevention as well as acute treatment of migraines in adults

Company provides formal response to misleading recently published short report

Soticlestat continues to appear to be safe and well-tolerated; the majority of the 11 patients showed a reduction in seizures All patients that have completed the Phase 2 ARCADE study to date have opted to enroll in the ENDYMION open-label extension study NEW YORK, March 30, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced initia

InnerScope Hearing Technologies signs an Agreement with Pursuant Health Inc. to launch its Hearing Loss Information Center to all 4,618 of Pursuant Health’s Wellness Screening Kiosks inside all Walmart and Walmart Neighborhood Market locations nationwide by June 2020.

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) will report its 2019 Fourth Quarter and Full-Year Financial Results on Monday, March 30, 2020 after the close of trading on NASDAQ.

CHASE Clinical Trial. On September 23, 2019, the Company announced findings from the pre-specified interim review of its ongoing CHASE clinical trial.